These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2507913)

  • 1. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox.
    Gorla NB; Ledesma OS; Barbieri GP; Larripa IB
    Mutat Res; 1989 Oct; 224(2):263-7. PubMed ID: 2507913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chagas' disease: clastogenic effect of nifurtimox and benznidazole in children].
    Moya PR; Trombotto GT
    Medicina (B Aires); 1988; 48(5):487-91. PubMed ID: 3151216
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of cytogenetic damage in chagasic children treated with benznidazole.
    Gorla NB; Ledesma OS; Barbieri GP; Larripa IB
    Mutat Res; 1988 Oct; 206(2):217-20. PubMed ID: 3140001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of sensitivity of sister-chromatid exchange for lymphocyte chromosomal damage detection caused by antichagasic treatment.
    Gorla NB; Ledesma OS; Barbieri GP; Larripa IB
    Toxicol Lett; 1991 Oct; 58(2):225-30. PubMed ID: 1949081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)].
    Cerisola JA; Neves da Silva N; Prata A; Schenone H; Rohwedder R
    Bol Chil Parasitol; 1977; 32(3-4):51-62. PubMed ID: 416834
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutagenicity of 2 anti-chagasic drugs and their metabolic deactivation.
    Nagel R; Nepomnaschy I
    Mutat Res; 1983; 117(3-4):237-42. PubMed ID: 6406881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-reacting antibodies (EVI antibodies) in nifurtimox-treated patients with Chagas's disease.
    Schmuñis GA; Cossio PM; Szarfman A; Coarasa L; Arana RM
    J Infect Dis; 1978 Sep; 138(3):401-4. PubMed ID: 100564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of antibody dependent cytotoxicity to Trypanosoma cruzi in chronic chagasic mice after treatment with nifurtimox.
    Chambó JG; Cabeza Meckert PM; Laguens RP
    Medicina (B Aires); 1988; 48(1):49-53. PubMed ID: 3146009
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of Chagas' disease with nifurtimox during the first months of life].
    Moya PR; Paolasso RD; Blanco S; Lapasset M; Sanmartino C; Basso B; Moretti E; Cura D
    Medicina (B Aires); 1985; 45(5):553-8. PubMed ID: 3939553
    [No Abstract]   [Full Text] [Related]  

  • 12. [Nifurtimox treatment of chronic Chagasic infection in children].
    Schenone H; Contreras M; Solari A; García A; Rojas A; Lorca M
    Rev Med Chil; 2003 Sep; 131(9):1089-90. PubMed ID: 14635599
    [No Abstract]   [Full Text] [Related]  

  • 13. [Nifurtimox as a prophylactic drug to prevent reactivation in chronic chagasic patients treated with corticoid for associated diseases].
    Rassi A; Neto VA; de Siqueira AF; Leite MS
    Rev Soc Bras Med Trop; 1998; 31(3):249-55. PubMed ID: 9612015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micronucleus formation in bone marrow of mice treated with nifurtimox or benznidazole.
    Gorla NB; Castro JA
    Toxicol Lett; 1985 Jun; 25(3):259-63. PubMed ID: 4012803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Longitudinal study of the persistence of the therapeutic action of nifurtimox and benznidazole in patients with chronic chagas infection].
    Schenone H; Rojas A; Alfaro E; Concha L; Aranda R
    Bol Chil Parasitol; 1981; 36(3-4):59-62. PubMed ID: 6812600
    [No Abstract]   [Full Text] [Related]  

  • 16. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibility of treatment in Chagas' disease].
    Prata A
    AMB Rev Assoc Med Bras; 1978 Apr; 24(4):140-2. PubMed ID: 98813
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox).
    Lelchuk R; Cardoni RL; Fuks AS
    Clin Exp Immunol; 1977 Dec; 30(3):434-8. PubMed ID: 414867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Etiologic therapy of Chagas' disease].
    Boainain E; Rassi A
    Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs].
    Levy AM; Pereira VL; Boainain E
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.